Qlaris Bio
Dedham, US · Founded 2019 · Delaware corporation · 6 known investors
Qlaris Bio is a clinical-stage biotechnology company developing therapies for ophthalmology conditions. Its lead candidate, QLS-111, is a topical eye-drop treatment for glaucoma that lowers intraocular pressure by targeting episcleral venous pressure.
BiotechMedical Devices
Founders & leadership
Qlaris Bio was founded in 2019 by Thurein Htoo.
TH
Thurein HtooFounder
FG
Fred GuerardPresident & Chief Executive Officer
BW
Barbara WirostkoNamed on SEC filing
Board
WH
RM
Ronald M. HuntBoard director
AD
Andrew DanielsonBoard director
AG
Adrienne GravesBoard director
AD
Andrew DanielsenBoard director
Investors · 6
Canaan PartnersStamford · $500K – $20Mvia Wende Hutton · board
abrdn plcreported · 2 sourcesEdinburgh
Correlation Venturesreported · 2 sourcesSan Francisco · $100K – $4M
Mayo Clinic Venturesreported · 2 sourcesRochester
New Leaf Venture Partnersreported · 2 sourcesNew York
Also in the syndicate · 1
Canaanlead
Reported raises · per SEC filings
Form D private placements$41.8M disclosed across 4 rounds · 2019–2026
▶$3.9MraisedJun 2026 · 8 investors · BiotechnologyRule 506(b)
▶$3.9MraisedJun 2026 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Barbara WirostkoExecutive Officer
- Adrienne GravesDirector
- Wende HuttonDirector
- Robert WarnerDirector
- Frederic GuerardExecutive Officer, Director
- Ronald M. HuntDirector
- Andrew DanielsonDirector
- Offering amount
- $3.9M
- Amount sold
- $3.9M
- First sale
- Jun 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.6MraisedNov 2025 · 8 investors · BiotechnologyRule 506(b)
▶$5.6MraisedNov 2025 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Adrienne GravesDirector
- Barbara WirostkoExecutive Officer
- Wende HuttonDirector
- Thurein HtooExecutive Officer, Director
- Ronald M. HuntDirector
- Andrew DanielsonDirector
- Offering amount
- $5.6M
- Amount sold
- $5.6M
- First sale
- Nov 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$24MraisedApr 2024 · 8 investors · BiotechnologyRule 506(b)
▶$24MraisedApr 2024 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Andrew DanielsonDirector
- Ronald M. HuntDirector
- Adrienne GravesDirector
- Thurein HtooExecutive Officer, Director
- Wende HuttonDirector
- Barbara WirostkoExecutive Officer
- Offering amount
- $24M
- Amount sold
- $24M
- First sale
- Apr 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$8.2MraisedAug 2019 · 6 investors · BiotechnologyRule 506(b)
▶$8.2MraisedAug 2019 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ron HuntDirector
- Wende HuttonDirector
- Barbara WirostkoExecutive Officer
- Thurein HtooExecutive Officer, Director
- Andrew DanielsenDirector
- Offering amount
- $27.3M
- Amount sold
- $8.2M
- First sale
- Aug 2019
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 7
by search overlapQuralis9 shared keywordsQurAlis develops precision therapies for amyotrophic lateral sclerosis (ALS) and related neurodegenerative diseases by targeting specific disease-causing genetic drivers and molecular mechanisms. The company was founded by neuroscientists from Harvard to translate emerging discoveries about disease pathways into treatment breakthroughs for ALS patients.
Trisaluslifesci8 shared keywordsTriSalus develops a therapeutic platform combining its Pressure-Enabled Drug Delivery (PEDD) method with immune-activating therapies to overcome intratumoral pressure and immunosuppression that limit treatment of liver and pancreatic tumors. The platform is designed to be used alongside systemic immunotherapies such as checkpoint inhibitors for cancer patients.
Claris Bio8 shared keywordsClaris Bio is a late-stage therapeutics company developing pharmacologic treatments for sight-threatening ophthalmic conditions with no or limited treatment options. Its lead candidate, CSB-001 (oremepermin alfa ophthalmic solution), targets limbal stem cell deficiency (LSCD), a blinding disease, with pivotal studies planned for 2027.
Aclaris Therapeutics8 shared keywordsAclaris develops investigational monoclonal antibodies and small-molecule inhibitors targeting immune pathways for the treatment of atopic, autoimmune, and respiratory diseases. The company's clinical and preclinical pipeline includes candidates in development for severe asthma, atopic dermatitis, and T-cell-mediated autoimmune conditions.
IQVIA8 shared keywordsIQVIA provides data, analytics, AI, and technology-driven services for life sciences and healthcare organizations, spanning clinical development, real world evidence generation, and commercial execution. It offers integrated solutions for clinical trials, regulatory and safety compliance, and market analytics, including agentic AI products for commercial and R&D teams.
Arcus Biosciences7 shared keywordsArcus Biosciences develops combination cancer therapies, producing small molecules and antibodies designed to be combined and advanced from Phase 1 studies through commercialization. The company focuses on oncology treatments guided by specific biologic mechanisms of cancer.
Alumis7 shared keywordsAlumis is a clinical-stage biopharmaceutical company developing a late-stage portfolio of targeted therapies for immune-mediated diseases. It focuses on small-molecule drug discovery and development in immunology and inflammation.
Companies competing with Qlaris Bio for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Qlaris Bio do?
- Qlaris Bio is a clinical-stage biotechnology company developing therapies for ophthalmology conditions. Its lead candidate, QLS-111, is a topical eye-drop treatment for glaucoma that lowers intraocular pressure by targeting episcleral venous pressure.
- Who founded Qlaris Bio?
- Qlaris Bio was founded by Thurein Htoo in 2019.
- Who are Qlaris Bio's investors?
- Qlaris Bio's investors include Canaan Partners, abrdn plc, Correlation Ventures, Mayo Clinic Ventures, New Leaf Venture Partners.
- How much funding has Qlaris Bio raised?
- Qlaris Bio has disclosed $41.8M raised across 4 rounds.
- Where is Qlaris Bio headquartered?
- Qlaris Bio is headquartered in Dedham, US.